Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2013
    IL-13Ra1 and Neuroinflammatory Damage in the MPTP Pre-Clinical Model of PD

    Study Rationale:                   
    Neuroinflammation has been proposed to contribute to both the pathogenesis and the progression of Parkinson's disease (PD). We recently showed that an important...

  • LRRK2 Role in Idiopathic Parkinson's Disease, 2013
    Phenotype Assay for LRRK2 in Parkinson's Disease Fibroblasts

    Objective/Rationale:             
    Variants of the LRRK2 gene are associated with overactivation of the LRRK2 protein’s activity and an increased risk of Parkinson's disease (PD). We have previously...

  • LRRK2 Challenge, 2013
    Investigating the Role of LRRK2 in Mycobacterial Infection

    Objective/Rationale:             
    Mutations in the LRRK2 gene are the most common known genetic risk factors for Parkinson's disease. Although we know that these mutations can cause Parkinson's disease...

  • LRRK2 Cohort Consortium Resource Request, 2013
    Alpha-synuclein and Other Biomarkers in Biological Samples of LRRK2 Parkinson’s Disease

    Objective/Rationale:
    Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s pathology have been investigated in Parkinson’s disease (PD), and abnormal CSF protein levels (tau and phosphorylated tau, beta...

  • Dyskinesia Challenge, 2013
    NOP Receptor Agonists for Preventing Levodopa-induced Dyskinesia

    Objective/Rationale:             
    Dyskinesia (involuntary fractured, jerky movements) is a debilitating side effect of long-term levodopa treatment for Parkinson’s motor symptoms. Previous studies have...

  • Cognition Biomarkers, 2013
    Alpha-synuclein and Cognitive Decline in Parkinson’s Disease

    Objective/Rationale:             
    Variability in the SNCA gene (which encodes alpha-synuclein, the protein that clumps in Parkinson’s disease) is a major risk factor for PD. Using next-generation...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.